Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 7/20 | 0.40 |
| ▸ | ADH1C | P00326 | 4/20 | 0.39 |
| ▸ | AGER | Q15109 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773489 | 0.84 | ALDH1A1 (0.39) | AGERMTNR1AL3MBTL1 | |
| SCHEMBL11288200 | 0.80 | AGER (0.41) | AGERMTNR1AL3MBTL1 | |
| SCHEMBL30231053 | 0.80 | — | — | |
| SCHEMBL23795173 | 0.79 | CCR5 (0.36) | AGER | |
| SCHEMBL3589654 | 0.79 | ADH1A (0.36) | ADH1AADH1CL3MBTL1ADH4 | |
| SCHEMBL27815168 | 0.79 | ADH1A (0.44) | ADH1AADH1CL3MBTL1 | |
| SCHEMBL4442911 | 0.78 | AGER (0.41) | AGERMTNR1AL3MBTL1 | |
| SCHEMBL16653682 | 0.78 | AGER (0.41) | AGERMTNR1AL3MBTL1 | |
| SCHEMBL3892850 | 0.77 | AGER (0.40) | AGERMTNR1AL3MBTL1 | |
| SCHEMBL967635 | 0.77 | L3MBTL1 (0.54) | ADH1AADH1CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010117939-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-9198907-B2 | Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent | PTC THERAPEUTICS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PTC THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | THE GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR2, CNR1, GPR119 | ADH1A 647/4885ADH1C 324/4885AGER 2947/4885 |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | ADH1A 1814/4885ADH1C 1931/4885AGER 4149/4885 |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | ADH1A 708/4885ADH1C 378/4885AGER 2919/4885 |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | ADH1A 1361/4885ADH1C 994/4885AGER 2509/4885 |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PREP, ENPEP, DNPEP | ADH1A 1060/4885ADH1C 990/4885AGER 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.